Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

Effects of treatment with fluoride on bone mineral density and fracture risk--a meta-analysis.

Vestergaard P, Jorgensen NR, Schwarz P, Mosekilde L.

Osteoporos Int. 2008 Mar;19(3):257-68. Epub 2007 Aug 15. Review.

PMID:
17701094
2.

Effects of parathyroid hormone alone or in combination with antiresorptive therapy on bone mineral density and fracture risk--a meta-analysis.

Vestergaard P, Jorgensen NR, Mosekilde L, Schwarz P.

Osteoporos Int. 2007 Jan;18(1):45-57. Epub 2006 Sep 2. Review.

PMID:
16951908
3.

Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial.

Bauer DC, Black DM, Garnero P, Hochberg M, Ott S, Orloff J, Thompson DE, Ewing SK, Delmas PD; Fracture Intervention Trial Study Group.

J Bone Miner Res. 2004 Aug;19(8):1250-8. Epub 2004 May 24.

4.

Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis.

Hatzigeorgiou C, Jackson JL.

Osteoporos Int. 2005 Aug;16(8):990-8. Epub 2005 Mar 3. Review.

PMID:
15744453
5.

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs.

Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM.

Am J Med. 2002 Mar;112(4):281-9.

PMID:
11893367
6.

Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX.

Kanis JA, Johansson H, Oden A, McCloskey EV.

Bone. 2009 Jun;44(6):1049-54. doi: 10.1016/j.bone.2009.02.014. Epub 2009 Feb 28.

PMID:
19254788
7.
8.

A comprehensive review of treatments for postmenopausal osteoporosis.

Häuselmann HJ, Rizzoli R.

Osteoporos Int. 2003 Jan;14(1):2-12. Review.

PMID:
12577179
9.
10.

Osteoporosis: trials and tribulations.

Seeman E.

Am J Med. 1997 Aug 18;103(2A):74S-87S; discussion 87S-89S. Review.

PMID:
9302899
12.

Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data.

Adachi JD, Rizzoli R, Boonen S, Li Z, Meredith MP, Chesnut CH 3rd.

Aging Clin Exp Res. 2005 Apr;17(2):150-6.

PMID:
15977464
13.

Fluoride for treating postmenopausal osteoporosis.

Haguenauer D, Welch V, Shea B, Tugwell P, Wells G.

Cochrane Database Syst Rev. 2000;(4):CD002825. Review.

PMID:
11034769
14.

Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.

Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD.

J Bone Miner Res. 2002 Jan;17(1):1-10.

15.

Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial.

Chapurlat RD, Palermo L, Ramsay P, Cummings SR.

Osteoporos Int. 2005 Jul;16(7):842-8. Epub 2004 Dec 3.

PMID:
15580479
16.

Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.

McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Kayan K, Beneton M, Jalava T, Pylkkänen L, Kenraali J, Aropuu S, Kanis JA.

J Bone Miner Res. 2004 May;19(5):728-36. Epub 2004 Jan 19.

17.

The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis. A randomized, controlled trial.

Reginster JY, Meurmans L, Zegels B, Rovati LC, Minne HW, Giacovelli G, Taquet AN, Setnikar I, Collette J, Gosset C.

Ann Intern Med. 1998 Jul 1;129(1):1-8.

PMID:
9652994
18.

Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial.

Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD.

Bone. 2003 Oct;33(4):522-32.

PMID:
14555255
19.

Disc space narrowing is associated with an increased vertebral fracture risk in postmenopausal women: the OFELY Study.

Sornay-Rendu E, Munoz F, Duboeuf F, Delmas PD; OFELY Study.

J Bone Miner Res. 2004 Dec;19(12):1994-9. Epub 2004 Sep 13.

20.

Comparison of nonrandomized trials with slow-release sodium fluoride with a randomized placebo-controlled trial in postmenopausal osteoporosis.

Pak CY, Adams-Huet B, Sakhaee K, Bell NH, Licata A, Johnston C, Rubin B, Bonnick S, Piziak V, Graham H, Ballard J, Berger R, Fears W, Breslau N, Rubin C.

J Bone Miner Res. 1996 Feb;11(2):160-8.

PMID:
8822339

Supplemental Content

Support Center